Evidence map›Paper›PMID 42592210›Full record

ReviewActa pharmaceutica Sinica. B2026

HIFs: The central drivers of tumors and their role as molecular switches in targeted therapy?

Yi Peng, Ying Che, Yingqi Zhao, Zheng Wang, Zhanlei Pei, Yanyun Hu, Yuhang Yin, Xiaolong Pan, Xiaoyun Hu, Minjie Wei and 1 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Acta pharmaceutica Sinica. B, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yi PengDepartment of Pharmacology, School of Pharmacy, China Medical University, Shenyang 110122, China.
Ying CheDepartment of Pharmacology, School of Pharmacy, China Medical University, Shenyang 110122, China.
Yingqi ZhaoDepartment of Pharmacology, School of Pharmacy, China Medical University, Shenyang 110122, China.
Zheng WangDepartment of Otorhinolaryngology, First Hospital of China Medical University, Shenyang 110001, China.
Zhanlei PeiDepartment of Pharmacology, School of Pharmacy, China Medical University, Shenyang 110122, China.
Yanyun HuDepartment of Pharmacology, School of Pharmacy, China Medical University, Shenyang 110122, China.
Yuhang YinDepartment of Pharmacology, School of Pharmacy, China Medical University, Shenyang 110122, China.
Xiaolong PanDepartment of Pharmacology, School of Pharmacy, China Medical University, Shenyang 110122, China.
Xiaoyun HuDepartment of Pharmacology, School of Pharmacy, China Medical University, Shenyang 110122, China.
Minjie WeiDepartment of Pharmacology, School of Pharmacy, China Medical University, Shenyang 110122, China.
Huizhe WuDepartment of Pharmacology, School of Pharmacy, China Medical University, Shenyang 110122, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hypoxia-inducible factors (HIFs) serve as the central signaling hub within the hypoxic tumor microenvironment, coordinating tumor proliferation, metastasis, and therapy resistance. This protein family comprises HIF-1

Indexed as

HIF-Targeting inhibitorsHypoxia-inducible factorsHypoxic tumor microenvironmentImmune regulationRegulation mechanismTherapeutic targetsTherapy resistanceTumor treatment

Identifiers

PMID42592210
PMCPMC13464082

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.